Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPMEHTA, Ravindra L.AWDISHU, LindaDAVENPORT, AndrewMURRAY, Patrick T.MACEDO, EtienneCERDA, JorgeCHAKARAVARTHI, RajHOLDEN, Arthur L.GOLDSTEIN, Stuart L.2019-05-302019-05-302015KIDNEY INTERNATIONAL, v.88, n.2, p.226-234, 20150085-2538https://observatorio.fm.usp.br/handle/OPI/31931Drug-induced kidney disease is a frequent cause of renal dysfunction; however, there are no standards to identify and characterize the spectrum of these disorders. We convened a panel of international, adult and pediatric, nephrologists and pharmacists to develop standardized phenotypes for drug-induced kidney disease as part of the phenotype standardization project initiated by the International Serious Adverse Events Consortium. We propose four phenotypes of drug-induced kidney disease based on clinical presentation: acute kidney injury, glomerular, tubular, and nephrolithiasis, along with the primary and secondary clinical criteria to support the phenotype definition, and a time course based on the KDIGO/AKIN definitions of acute kidney injury, acute kidney disease, and chronic kidney disease. Establishing causality in drug-induced kidney disease is challenging and requires knowledge of the biological plausibility for the specific drug, mechanism of injury, time course, and assessment of competing risk factors. These phenotypes provide a consistent framework for clinicians, investigators, industry, and regulatory agencies to evaluate drug nephrotoxicity across various settings. We believe that this is the first step to recognizing drug-induced kidney disease and developing strategies to prevent and manage this condition.engrestrictedAccessacute kidney injuryadverse reactiondrugsglomerulonephritishypersensitivitynephrotoxicityexperienceinjuryakiarticleCopyright NATURE PUBLISHING GROUP10.1038/ki.2015.115Urology & Nephrology1523-1755